Imunopatogenesis Asma

Resti Yudhawati, Desak Putu Agung Krisdanti

Abstract views = 1633 times | downloads = 49933 times


Asthma is a chronic inflammatory disease of the airways characterized by recurrent wheezing, shortness of breath, chest tightness and cough especially at night and or early morning. Airflow resistance in asthma were caused by changes in the airways include bronchoconstriction, airway edema, hyperresponsiveness and airway remodeling. The inflammatory response in asthma patients varies among individuals, whether it can be immediate or late (slow-type) response. Different types of cells are known to play role in this process, especially mast cells, eosinophils, T lymphocytes, macrophages, neutrophils and epithelial cells. Degranulation of mast cells in the airways release inflammatory mediators and various metabolites that directly lead to smooth muscle hypersponsive resulting in airway obstruction. While eosinophil cells, mast cells and lymphocytes associated with slow-type responses, will release various mediators including leukotriene, prostaglandins and a number of proinflammatory cytokines. Type 2 immune response in the lower respiratory tract is a central immunologic process in asthma. This type 2 immune response is mediated by Th2 cells of CD4 + and IgE. The CD4 + Th2 cell is characterized by the large amount of transacting T-cell-specific transcription factor GATA-3 and the secretion of type 2 cytokines (IL-4, IL-5, IL-9 and IL-13). Excessive type 2 cytokines in the lower airway will trigger IgE-mediated hypersensitivity, epithelial cell activation, inflammatory cell inflation mediation into the airways, and cause remodeling responses in the epithelium and subepithelial matrices. This inflammatory cascade of type 2 cytokines is the pathological basis of the main symptoms of asthma.


Asthma, Type 2 immune response, CD4 + T cells, IgE

Full Text:



Perhimpunan Dokter Paru Indonesia (PDPI). Asma. Pedoman diagnosis & penatalaksanaan di Indonesia 2011.

Pynn MC, Thornton CA, Davies GA. Asthma pathogenesis. Pulmo RJ. 2012; 21(2): 11–17.

Global Initiative for Asthma (GINA). Global strategy for ashtma management and prevention. Revised 2014.

Maranatha D, Wibisono M Jusuf, Winariani, et al. Buku Ajar Ilmu Penyakit Paru. Departemen Pulmonologi dan Ilmu Kedokteran Respirasi, FK Unair-RSUD dr Soetomo Surabaya. 2010, hal. 63.

Centers for Disease Control and Prevention (CDC). Vital signs: asthma prevalence, disease characteristic, and self-management education - United States, 2001–2009. Morbidity and Mortality Weekly Report. 2011; 60: 547–52.

Depkes RI. Riset kesehatan dasar. RISKESDAS 2007. Jakarta: Departemen Kesehatan, Republik Indonesia, 2008.

Murray JF, Nadel JA, Broaddus VC. Asthma: Pathogenesis and phenotypes. Murray & Nadel’s Textbook of Respiratory Medicine sixth edition. 2016 (2): 713–725.

Lambrecht BN, Hammad H. The immunology of asthma. Immunology of the lung. 2015(16): 45–50.

Barnes PJ. Pathophysiology of asthma. Eur Respir Mon. 2003, 23: 84–113.

Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Immunology. 2008 (8): 183–191.

National Heart Lung Blood Institute (NHLBI). Definition, pathophysiology and pathogenesis of asthma, and natural history of asthma. 2007: 11–28.

Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really different?. Eur Respir Rev. 2013; 22: 44–52.

Buc M, Dzurilla M, Vrlik M, Bucova M. Immunopathogenesis of bronchial asthma. Arch Immunol Ther Exp. 2009, 57: 331–344.

Loytomaki M. Immunopathogenesis of asthma and atopic diseases – the specific role of a selected panel of genes in human t helper cell differentiation. 2007: 11–33.


  • There are currently no refbacks.

Copyright (c) 2017 Resti Yudhawati, Desak Putu Agung Krisdanti

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

View My Stats



Creative Commons License

JR (p-ISSN: 2407-0831e-ISSN: 2621-8372) is licensed under Creative Commons Attribution-ShareAlike 4.0 International License.